Recombinant MAPT (Semorinemab Biosimilar) antibody
This Humanized Chimeric antibody specifically detects MAPT (Semorinemab Biosimilar) in ELISA and WB. It exhibits reactivity toward Human.
Catalog No. ABIN7538081
$336.06
Plus shipping costs $50.00
Shipping to:
United States
Delivery in 7 to 10 Business Days
Quick Overview for Recombinant MAPT (Semorinemab Biosimilar) antibody (ABIN7538081)
Target
MAPT (Semorinemab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Humanized
Clonality
Chimeric
Conjugate
This MAPT (Semorinemab Biosimilar) antibody is un-conjugated
Application
ELISA, Western Blotting (WB)
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Semorinemab Biosimilar - Anti-MAPT mAb - Research Grade
-
Characteristics
- Antibody Type: IgG4-kappa
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Purity
- > 85%
-
Isotype
- IgG4
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS buffer PH7.5
-
Storage
- -80 °C
-
Storage Comment
- store at -80°C
-
-
- MAPT (Semorinemab Biosimilar)
-
Target Type
- Biosimilar
-
Background
- Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease.
-
CAS-No
- 2159141-27-0
Target
-
You are here:
